Across TCGA pan-cancer cohorts, RTP4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RTP4 data layer compared with 24 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RTP4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTP4 expression acts as an unfavorable survival marker.
UCEC and LUAD are the cancer types where RTP4 mass-spec protein most reproducibly stratifies survival.